TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Sponsor: Theralase® Technologies Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$2,772,000

Rescue Site Savings

+$1,848,000

Unlock Full NCT03945162 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03945162 Rescue Dossier →